Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Relationship between 4-Hydroxynonenal and Agitation Severity in Alzheimer’s Disease

FY 2022-23

Summary
Alzheimer’s disease (AD) is the most common cause of dementia affecting memory, thinking, and behaviour, and is increasing in prevalence among older adults. Agitation is a symptom of AD that involves aggressive verbal or physical activity and emotional distress and is commonly seen in people with moderate to severe dementia. Research suggests that oxidative stress, a process referring to the buildup of toxic chemicals in the blood produced by cells generating energy, is involved in AD. When these toxic chemicals come into contact with fat molecules within cells, their reaction releases a compound called 4-hydroxynonenal (4-HNE) which has been found in high concentrations in the blood of people with AD and other diseases involving thinking difficulties. The relationship between 4-HNE and agitation levels in AD although previously explored, has not been studied extensively. This study will measure the concentration of 4-HNE in the blood of patients with AD to determine its relation to agitation severity they experience. Agitation will be measured using questionnaires with caregivers. We propose that higher 4-HNE in the blood will be associated with more severe agitation in AD patients. Agitation increases the risk of hospitalization and death and decreases the quality of life for AD patients and their caregivers. Medications currently used to treat agitation are limited in effectiveness and have many unwanted side effects. Understanding the mechanisms underlying agitation can help us develop medications that are able to specifically target this symptom, which will reduce side effects and increase quality of life for millions of older adults with AD.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486589
Name
Chinnameyyappan Arun
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Relationship between 4-Hydroxynonenal and Agitation Severity in Alzheimer’s Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
4-Hydroxynonenal; Aging; Agitation; Alzheimer'S Disease; Biomarker; Dementia; Lipid Peroxidation; Memory; Neuropsychiatric Symptoms; Oxidative Stress
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia affecting memory, thinking, and behaviour, and is increasing in prevalence among older adults. Agitation is a symptom of AD that involves aggressive verbal or physical activity and emotional distress and is commonly seen in people with moderate to severe dementia. Research suggests that oxidative stress, a process referring to the buildup of toxic chemicals in the blood produced by cells generating energy, is involved in AD. When these toxic chemicals come into contact with fat molecules within cells, their reaction releases a compound called 4-hydroxynonenal (4-HNE) which has been found in high concentrations in the blood of people with AD and other diseases involving thinking difficulties. The relationship between 4-HNE and agitation levels in AD although previously explored, has not been studied extensively. This study will measure the concentration of 4-HNE in the blood of patients with AD to determine its relation to agitation severity they experience. Agitation will be measured using questionnaires with caregivers. We propose that higher 4-HNE in the blood will be associated with more severe agitation in AD patients. Agitation increases the risk of hospitalization and death and decreases the quality of life for AD patients and their caregivers. Medications currently used to treat agitation are limited in effectiveness and have many unwanted side effects. Understanding the mechanisms underlying agitation can help us develop medications that are able to specifically target this symptom, which will reduce side effects and increase quality of life for millions of older adults with AD.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chinnameyyappan, Arun
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~